Kidney Outcomes With Rituximab Versus Cyclophosphamide in Crescentic ANCA-Associated Glomerulonephritis: Contextualizing Observational Findings.

Kidney Int Rep · 2026 · PMC13196301 · PMID 42180823

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Indeed, in the plasma exchange and glucocorticoid vasculitis assessment (PEXIVAS trial) 3 patients treated with RTX in the reduced-dose glucocorticoid arm showed a trend for lower response compared with those receiving standard-dose glucocorticoids.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.